pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
apexian-pharmaceuticals PRESS RELEASE ARCHIVE
Jan 22, 2020
Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
Jul 2, 2019
Apexian Pharmaceuticals' Clinical Candidate, APX3330, to Be Studied in Diabetic Models of Preleukemic Cells With Specific Mutations to Leukemia
Dec 19, 2018
Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia
Dec 12, 2018
Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia in Preclinical Models
Dec 5, 2018
Apexian Pharmaceuticals Presents Data on Their Lead Drug for Anti-Chemotherapy-Induced Peripheral Neuropathy (CIPN), APX3330, at ASCO Palliative Care and Symptom Management Meeting
Apr 25, 2018
Apexian Pharmaceuticals’ Dr. Mark Kelley Recognized as an Outstanding Researcher at Indiana University/Purdue University IUPUI
Apr 16, 2018
Apexian Pharmaceuticals to Present Two Poster Sessions at AACR Meeting in Chicago – April 14-18, 2018
Jan 24, 2018
Apexian Pharmaceuticals Opens Phase 1 Clinical Study of APX3330 in Patients with Solid Tumors
Nov 29, 2017
Apexian Pharmaceuticals is Closing a Series A Round to Initiate Phase 1 Trial
